In experimental atherosclerosis, hematopoietic or global TREM2 deficiency increased, whereas treating Ldlr−/− mice with the TREM2 agonistic antibody 4D9 (ref. 11) decreased, necrotic core formation. This evidence concerns the gene TREM2 and atherosclerosis.